Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration‐Resistant Prostate Cancer: A Real‐World Multi‐Intuitional Analysis
In mCRPC patients of ≥ 80 years of age, CBZ showed similar safety and efficacy to younger patients. Our findings suggest that CBZ treatment with appropriate dose modification and prophylactic AE treatments may be still beneficial for elderly mCRPC patients in the current aging population.
Authors
- Junichiro Hirata
- Yukari Bando (ORCID: https://orcid.org/0000-0001-7736-1216)
- Takuto Hara (ORCID: https://orcid.org/0000-0003-4524-2815)
- Tomoaki Terakawa (ORCID: https://orcid.org/0000-0002-4447-6516)
- Yasuyoshi Okamura (ORCID: https://orcid.org/0000-0002-8466-3949)
- Yoji Hyodo (ORCID: https://orcid.org/0000-0002-9553-0981)
- Koji Chiba (ORCID: https://orcid.org/0000-0001-5575-0667)
- Kotaro Suzuki (ORCID: https://orcid.org/0000-0003-4589-9251)
- Hideaki Miyake
- Jun Teishima (ORCID: https://orcid.org/0009-0004-7018-5095)
Institutions
- Kobe University (JP)
Publication Details
- Journal
- The Prostate
- Published
- 2025-03-16
- DOI
- https://doi.org/10.1002/pros.24889
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52